PI3 kinase as a therapeutic target for diseases associated with mutations in the catalytic domain of Kit.

被引：0
|
作者：
Linnekin, D [1 ]
Krupa, S [1 ]
机构：
[1] NCI, Frederick Canc Res Facil, Basic Res Lab, Frederick, MD USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
712
引用
收藏
页码：190A / 190A
页数：1
相关论文
共 50 条
  • [1] PI3 Kinase Pathway Mutations in Human Cancers
    Gray, Joe W.
    JAMA ONCOLOGY, 2016, 2 (12) : 1543 - 1544
  • [2] Assessment of PI3 kinase as a druggable target in melanoma
    Aziz, S. A.
    Pick-Golan, E.
    McCarthy, M. M.
    Flaherty, K. T.
    Camp, R. L.
    Rimm, D. L.
    Kluger, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Mutations of the catalytic domain of PI3 kinase and correlation with clinical outcome in trastuzumab-treated metastatic breast cancer (MBC).
    Cook, J. W.
    Paxinos, E.
    Goodman, L. J.
    Ali, S. M.
    Leitzel, K.
    Koestler, W.
    Rivera, A.
    Weidler, M.
    Huang, W.
    Sperinde, J.
    Williams, S. J.
    Bates, M.
    Lipton, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] PI3 kinase mutations occur early in breast carcinoma
    Dunlap, J. B.
    Le, C.
    Patterson, J.
    Town, A.
    Heinrich, M. C.
    Corless, C. L.
    Troxell, M. L.
    LABORATORY INVESTIGATION, 2007, 87 : 29A - 29A
  • [5] PI3 kinase mutations occur early in breast carcinoma
    Dunlap, J. B.
    Le, C.
    Patterson, J.
    Town, A.
    Heinrich, M. C.
    Corless, C. L.
    Troxell, M. L.
    MODERN PATHOLOGY, 2007, 20 : 29A - 29A
  • [6] Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
    Zhu, Guangrong
    Shi, Jun
    Zhang, Shaoting
    Guo, Yue
    Huang, Ling
    Zhao, Hui
    Jiang, Yideng
    Sun, Jianmin
    CELL AND BIOSCIENCE, 2020, 10 (01):
  • [7] Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
    Guangrong Zhu
    Jun Shi
    Shaoting Zhang
    Yue Guo
    Ling Huang
    Hui Zhao
    Yideng Jiang
    Jianmin Sun
    Cell & Bioscience, 10
  • [8] PI3 KINASE AND CHECKPOINT INHIBITION: A POTENTIALLY NOVEL THERAPEUTIC STRATEGY FOR GLIOBLASTOMA (GBM)
    Jalali, Ali
    Siddik, Abu Bakar
    Yu, Kwanhu
    Tobin, Richard P.
    Hay, Charles E.
    Aminkeng, Folefac
    Fonkem, Ekokobe
    Newell-Rogers, M. Karen
    NEURO-ONCOLOGY, 2024, 26
  • [9] PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients
    Kaspar Draaisma
    Maarten M. J. Wijnenga
    Bas Weenink
    Ya Gao
    Marcel Smid
    P. Robe
    Martin J. van den Bent
    Pim J. French
    Acta Neuropathologica Communications, 3
  • [10] PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients
    Draaisma, Kaspar
    Wijnenga, Maarten M. J.
    Weenink, Bas
    Gao, Ya
    Smid, Marcel
    Robe, P.
    van den Bent, Martin J.
    French, Pim J.
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2015, 3 : 88
12345